Childhood Cancer Data Initiative Annual Symposium (Abstract Registration): Submission #41

serial: '41'
sid: '148393'
uuid: 0152f5c9-da71-4180-9908-037cc01084ed
uri: /nci/ccdisymposium/abstract
created: '1754589324'
completed: '1754591066'
changed: '1754591066'
in_draft: '0'
current_page: ''
remote_addr: 10.208.28.64
uid: '0'
langcode: en
webform_id: ccdi_symposium_abstract
entity_type: node
entity_id: '2139'
locked: '0'
sticky: '0'
notes: ''
metatag: meta
data:
  authors_:
    - add_author_degree: M.S.
      add_author_first_name: Sidney
      add_author_last_name: Benich
      add_author_middle: 'N'
      add_author_organization: 'Dana-Farber Cancer Institute'
    - add_author_degree: B.A.
      add_author_first_name: Stephanie
      add_author_last_name: Suser
      add_author_middle: ''
      add_author_organization: 'Memorial Sloan Kettering Cancer Center'
    - add_author_degree: MBA
      add_author_first_name: Evelina
      add_author_last_name: Ceca
      add_author_middle: ''
      add_author_organization: 'Dana-Farber Cancer Institute'
    - add_author_degree: ''
      add_author_first_name: Liliana
      add_author_last_name: Rodriguez
      add_author_middle: ''
      add_author_organization: 'Memorial Sloan Kettering Cancer Center'
    - add_author_degree: B.E.
      add_author_first_name: Madhumitha
      add_author_last_name: Sridharan
      add_author_middle: ''
      add_author_organization: 'Dana-Farber Cancer Institute'
    - add_author_degree: B.S.
      add_author_first_name: Julian
      add_author_last_name: Schwartz
      add_author_middle: ''
      add_author_organization: 'Memorial Sloan Kettering Cancer Center'
    - add_author_degree: B.S.
      add_author_first_name: Zachary
      add_author_last_name: Kahn
      add_author_middle: ''
      add_author_organization: 'Dana-Farber Cancer Institute'
    - add_author_degree: M.S.
      add_author_first_name: Anita
      add_author_last_name: Bowman
      add_author_middle: ''
      add_author_organization: 'Memorial Sloan Kettering Cancer Center'
    - add_author_degree: Ph.D.
      add_author_first_name: Joseph
      add_author_last_name: White
      add_author_middle: ''
      add_author_organization: 'Dana-Farber Cancer Institute'
    - add_author_degree: Ph.D.
      add_author_first_name: Rose
      add_author_last_name: Brannon
      add_author_middle: ''
      add_author_organization: 'Memorial Sloan Kettering Cancer Center'
    - add_author_degree: Ph.D.
      add_author_first_name: Wendy
      add_author_last_name: London
      add_author_middle: B
      add_author_organization: 'Dana-Farber Cancer Institute'
    - add_author_degree: M.D.
      add_author_first_name: Neerav
      add_author_last_name: Shukla
      add_author_middle: 'N'
      add_author_organization: 'Memorial Sloan Kettering Cancer Center'
    - add_author_degree: 'M.D., MMSc'
      add_author_first_name: Katherine
      add_author_last_name: Janeway
      add_author_middle: A
      add_author_organization: 'Dana-Farber Cancer Institute'
  abstract: 'Background: Approaches to obtaining structured clinical oncology data from the medical record are not standardized. PRISSMM was developed to reliably and reproducibly capture real-world oncology clinical data for adult solid malignancies from the medical record. We adapted the PRISSMM method to pediatric solid tumors(pediPRISSM) and assessed the feasibility of using pediPRISSMM to determine stage at presentation and progression-free survival(PFS) in patients with Ewing sarcoma(EWS).  Methods: Patients diagnosed with EWS who had tumor molecular profiling had medical records abstracted using pediPRISSMM at two institutions. Staging was derived from disease site information from imaging performed during staging (4 weeks from diagnosis). PFS from the diagnosis was based on disease status from radiology reports(PFSimaging) and chemotherapy drug regimen start and stop dates(PFSdrugs). Results: 158 patients with a confirmed EWS-associated fusion were included. Median age at diagnosis was 17 years (range of 1-75), 63% were male and 80% had primary bone disease. Currently, complete pediPRISSM data are available for 43 patients. It was possible to derive stage from pediPRISSMM radiology data for 63% of patients. PFSimaging and PFSdrugs were concordant in 74% of patients. Medical record review for patients with a difference of >6 weeks in PFS revealed multi-institutional care as the most common reason for discordance. Conclusions: Although further analysis is ongoing, these data support the universal implementation of accurate staging forms as part of routine clinical documentation.  Concordant findings using PFSimaging and PFSdrugs were achieved in the majority of patients, with highest success seen in patients treated at single institutions.'
  abstract_title_: 'Pediatric PRISSMM model for real world medical record data to capture stage, treatment and cancer outcomes'
  email_address_: sidneyn_benich@dfci.harvard.edu
  institution_: 'Dana-Farber Cancer Institute'
  presenting_author_: 'Sidney Benich'